<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062478</url>
  </required_header>
  <id_info>
    <org_study_id>KTN20405</org_study_id>
    <nct_id>NCT00062478</nct_id>
  </id_info>
  <brief_title>Study of Karenitecin (BNP1350) in Patients With Brain Tumors</brief_title>
  <official_title>Phase 2 Treatment of Adults With Primary Malignant Glioma With Karenitecin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioNumerik Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioNumerik Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a
      treatment of adults with brain tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Tumor Response Rate</measure>
    <time_frame>Randomization to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Randomization to date of death due to any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Safety</measure>
    <time_frame>Randomization to end of study participation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Brain Neoplasms</condition>
  <condition>Malignant Neoplasms, Brain</condition>
  <condition>Brain Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Karenitecin for intravenous use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Karenitecin (BNP1350)</intervention_name>
    <description>Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Karenitecin also referred to as BNP1350</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or
             recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic
             oligodendroglioma.

          -  Evidence of measurable recurrent or residual primary CNS neoplasm.

          -  An interval of at least 3 weeks between prior surgical resection or 6 weeks between
             prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is
             unequivocal evidence of tumor progression after surgery, radiotherapy, or
             chemotherapy.

          -  Hematocrit &gt; 29%, ANC &gt; 1,500, platelets &gt; 125,000

          -  Serum creatinine &lt; 1.5 mg/dl, BUN &lt; 25 mg/dl, serum SGOT and bilirubin &lt; 1.5 times
             upper limit of normal

          -  Negative pregnancy test for female patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>For Information call 210-614-1701 for a site near you</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2003</study_first_submitted>
  <study_first_submitted_qc>June 11, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2003</study_first_posted>
  <last_update_submitted>September 20, 2017</last_update_submitted>
  <last_update_submitted_qc>September 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

